Division of Endocrinology and Diabetes, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
Division of Pediatric Endocrinology, Department of Pediatrics, New York Medical College, Valhalla, NY.
J Pediatr. 2016 Jan;168:212-219. doi: 10.1016/j.jpeds.2015.09.045. Epub 2015 Oct 17.
To evaluate thresholds of various biomarkers for defining excess insulin activity to recognize congenital hyperinsulinism.
This was a retrospective chart review of diagnostic fasting tests in children with ketotic hypoglycemia (n = 30) and genetically/pathology confirmed congenital hyperinsulinism (n = 28). Sensitivity and specificity for congenital hyperinsulinism were determined for plasma insulin, β-hydroxybutyrate, free fatty acids (FFA), C-peptide, insulin-like growth factor binding protein-1 (IGFBP-1), and the glycemic response to glucagon (through the glucagon stimulation test [GST]) at the time of hypoglycemia.
Only 23 of the 28 subjects with congenital hyperinsulinism had detectable insulin (median, 6.7 μIU/mL), and insulin was undetectable in all subjects with ketotic hypoglycemia. Compared with ketotic hypoglycemia, subjects with congenital hyperinsulinism had higher GST values (57 vs 13 mg/dL; ΔGST ≥30 mg/dL in 24 of 27 subjects with congenital hyperinsulinism vs 0 of 30 subjects with ketotic hypoglycemia) and C-peptide levels (1.55 vs 0.11 ng/mL), with lower levels of FFA (0.82 vs 2.51 mM) and IGFBP-1 (59.5 vs 634 ng/mL). At the time of hypoglycemia, the upper limits of β-hydroxybutyrate and FFA in subjects with congenital hyperinsulinism were higher than reported previously (β-hydroxybutyrate <1.8 mM and FFA <1.7 mM), providing the best sensitivity for congenital hyperinsulinism vs ketotic hypoglycemia. A C-peptide level ≥0.5 ng/mL was 89% sensitive and 100% specific, and an IGFBP-1 level ≤110 ng/mL was 85% sensitive and 96.6% specific.
Because low or undetectable insulin level during hypoglycemia does not exclude the diagnosis of hyperinsulinism, C-peptide and IGFBP-1 may inform the diagnosis of congenital hyperinsulinism. In this group of children with well-defined congenital hyperinsulinism, thresholds for "suppressed" β-hydroxybutyrate and FFA are higher than previously reported levels.
评估各种生物标志物定义胰岛素过度活性的阈值,以识别先天性高胰岛素血症。
这是一项对伴有酮症性低血糖(n=30)和经基因/病理确诊的先天性高胰岛素血症(n=28)儿童的诊断性空腹试验的回顾性图表审查。在低血糖时,评估胰岛素、β-羟丁酸、游离脂肪酸(FFA)、C 肽、胰岛素样生长因子结合蛋白-1(IGFBP-1)和胰高血糖素的血糖反应(通过胰高血糖素刺激试验[GST])对先天性高胰岛素血症的敏感性和特异性。
仅 28 例先天性高胰岛素血症患者中的 23 例可检测到胰岛素(中位数 6.7 μIU/mL),所有酮症性低血糖患者均未检测到胰岛素。与酮症性低血糖相比,先天性高胰岛素血症患者的 GST 值更高(57 与 13 mg/dL;27 例先天性高胰岛素血症患者中有 24 例 GST 值增加≥30 mg/dL,而 30 例酮症性低血糖患者中无一例增加),C 肽水平更高(1.55 与 0.11ng/mL),FFA 和 IGFBP-1 水平更低(0.82 与 2.51 mM 和 59.5 与 634 ng/mL)。低血糖时,先天性高胰岛素血症患者的β-羟丁酸和 FFA 上限高于先前报道(β-羟丁酸<1.8 mM 和 FFA<1.7 mM),对先天性高胰岛素血症与酮症性低血糖的诊断具有最佳敏感性。C 肽水平≥0.5ng/mL 的敏感性为 89%,特异性为 100%,IGFBP-1 水平≤110ng/mL 的敏感性为 85%,特异性为 96.6%。
由于低血糖时胰岛素水平低或无法检测并不能排除高胰岛素血症的诊断,C 肽和 IGFBP-1 可能有助于先天性高胰岛素血症的诊断。在这群明确诊断为先天性高胰岛素血症的儿童中,“抑制”β-羟丁酸和 FFA 的阈值高于先前报道的水平。